desipramine has been researched along with Day Blindness in 1 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flores, DL | 1 |
| Alvarado, I | 1 |
| Wong, ML | 1 |
| Licinio, J | 1 |
| Flockhart, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00265291] | Phase 2 | 700 participants (Actual) | Interventional | 1999-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for desipramine and Day Blindness
| Article | Year |
|---|---|
Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans.
Topics: Adult; Cytochrome P-450 CYP2D6; Depression; Desipramine; Double-Blind Method; Fluoxetine; Humans; Hy | 2004 |